• The Latest: Panel studies illness cause in vaccine trial

    16 days ago - By Stl Today

    NEW BRUNSWICK, N.J. - Johnson & Johnson executives say it will be a few days before they know more about an unexplained illness in one participant that caused a temporary pause in its late-stage COVID-19 vaccine study.
    Read more ...

     

  • J&J Investors Are Fixated on Vaccines Like Everyone Else

    J&J Investors Are Fixated on Vaccines Like Everyone Else

    16 days ago - By Washington Post

    A setback in the drug giant's Covid-19 trial overshadowed good financial results. It's not the first and won't be the last.
    Read more ...

     

  • Johnson & Johnson Vaccine Trial Paused Due To 'Unexplained Illness' In Participant

    Johnson & Johnson Vaccine Trial Paused Due To 'Unexplained Illness' In Participant

    17 days ago - By NPR

    The company said it had paused further dosing in all of its COVID-19 vaccine candidate clinical trials while it investigated the volunteer's illness.
    Read more ...

     

  • Johnson & Johnson falls despite earnings beat after pausing COVID-19 vaccine trial due to unexpected illness

    Johnson & Johnson falls despite earnings beat after pausing COVID-19 vaccine trial due to unexpected illness

    17 days ago - By Business Insider

    Summary List Placement
    Johnson & Johnson fell as much as 3% on Tuesday after it temporarily paused its COVID-19 vaccine trial due to an "unexpected illness" in a trial participant.
    "Adverse events - illnesses, accidents, etc. - even those that are serious, are an expected part of any clinical study, especially large studies," Johnson & Johnson said in a statement.
    The pause in Johnson & Johnson's COVID-19 vaccine trial overshadowed its third quarter earnings results released on Tuesday, which beat analyst estimates and included a full-year guidance raise.
    Visit Business Insider's homepage...
    Read more ...

     

  • Johnson & Johnson falls despite earnings beat after pausing COVID-19 vaccine trial due to unexpected illness

    17 days ago - By Business Insider

    FILE floor of the NYSE in New York
    Reuters
    Johnson & Johnson fell as much as 3% on Tuesday after it temporarily paused its COVID-19 vaccine trial due to an "unexpected illness" in a trial participant. "Adverse events - illnesses, accidents, etc. - even those that are serious, are an expected part of any clinical study, especially large studies," Johnson & Johnson said in a statement. The pause in Johnson & Johnson's COVID-19 vaccine trial overshadowed its third quarter earnings results released on Tuesday, which beat analyst estimates and included a full-year guidance raise. Visit Business...
    Read more ...